Belfast
Fri 30 Jan 2026
12:30 PM - 08:00 PM (1 day)
A regional educational gathering to explore the latest developments in Prostate Cancer care locally, with content provided by leading urologists, oncologists and radiologists from the UK and Ireland.
Date: Friday 30th January 2026
Time: 12:30pm – 8pm
Location: Crowne Plaza Shaw’s Bridge, 117 Milltown Road, Belfast, BT8 7XP
This event will facilitate the dissemination of best practice educational content to local cancer service clinicians, provided by key opinion leaders in Prostate Cancer care, both locally and nationally. The multi-disciplinary nature of the meeting agenda and faculty, with Urologists, Oncologists and Radiologists represented, will ensure knowledge transfer of best practices is provided for clinicians working in all aspects of prostate cancer care in the UK and Ireland.
Agenda
Arrival: 12:30pm
Lunch on arrival | Sandwiches & Wraps
Session 1: 1:30pm-3:30pm
Chairs’ Remarks | Professor Suneil Jain
Keynote Talk 1 & Discussion | Anders Bjartell: “Complex robot assisted radical prostatectomy, including salvage”
Keynote Talk 2 & Discussion | Professor Vincent Gnanapragasam: “The critical importance of understanding prognosis when counselling men with newly diagnosed prostate cancer”
Keynote Talk 3 & Discussion | Professor Suneil Jain: “Updates on Prostate SABR”
Local Talk 1 & Discussion | Laura Feeney: “Overview on the management of metastatic hormone sensitive prostate cancer”
Interval: 3:30pm-4pm
Tea/Coffee & Shortbread
Session 2: 4pm-6pm
Chairs’ remarks | Professor Joe O’Sullivan
Local Talk 2 & Discussion | Dr Aidan Cole: “SABR for oligomets”
Keynote Talk 4 & Discussion | Anders Bjartell: “Indications and reporting of PSMA PET-CT”
Keynote Talk 5 & Discussion | Vincent Gnanapragasm: “An evidence-based approach to risk stratified active surveillance management of early prostate cancer”
Chairs’ Closing Remarks | Professor Suneil Jain
Dinner: 6:00pm
3-Course Buffet
Event Chairs
Professor Suneil Jain & Professor Joe O’Sullivan
Professor Jain, Professor of Clinical Oncology at Queen’s University Belfast and Consultant in Clinical Oncology, NI Cancer Centre, is an internationally recognised expert in the management of prostate cancer. He treats patients with prostate cancer with advanced radiotherapy (stereotactic radiotherapy and brachytherapy) and drug therapy (chemotherapy, hormone therapy). He carried an international fellowship at University of Toronto in prostate cancer.
He is an innovator working to reduce side-effects and improve outcomes from prostate cancer treatment; he performed the first transperineal prostate biopsies, the first transperineal fiducial marker insertion and the first SpaceOAR insertion in Northern Ireland. He also introduced new services to NI, HDR brachytherapy for prostate cancer and stereotactic radiotherapy for prostate cancer and oligometastatic disease. He leads multiple drug and radiotherapy trials in Northern Ireland. He is Chief Investigator for the global phase III SABRE study, the largest study (500 patients) to investigate the use of peri-rectal spacers in localised prostate cancer treated with SBRT. He is Clinical Lead for the PACE NODES trial, recruiting 1128 patients with high risk prostate cancer treated with SBRT to prostate +/- pelvic lymph nodes. He is Co-Director of the Prostate Cancer Centre of Excellence (ProEx).
Professor O’Sullivan (Consultant Clinical Oncologist, Belfast Trust and Professor of Radiation Oncology QUB) is an academic clinical oncologist with a passion for the treatment of patients with Prostate Cancer. He is driven by a desire to improve outcomes from all aspects of this disease and to develop new treatments in the fields of External Beam Radiation Therapy, and Bone-seeking radionuclide therapy. Throughout his academic medical career, Professor O’Sullivan has been committed to improving the lives of patients with prostate cancer through research and innovation.
Since joining the staff of Queen’s University Belfast in 2004, Professor O’Sullivan has established the clinical research programme in Prostate Cancer which is now recognised as a Centre of Excellence and led a major technological development programme in radiation oncology. Through more than 30 clinical trials and close collaboration with scientific colleagues in The Patrick G Johnston Centre for Cancer Research (formerly CCRCB), Joe has played a key role in building the university’s international reputation for world-leading research in Prostate Cancer. Professor Joe O’Sullivan’s research career takes him all around the globe, speaking on his specialist topic of molecular radiotherapy such as Radium-223 in metastatic Prostate Cancer.
